Trifluridine/tipiracil hydrochloride in the treatment of polytreated metastatic colorectal carcinoma: a cost-effectiveness analysis in the private payer perspective in Brazil

Abstract

Objective: To determine the cost-effectiveness analysis of trifluridine/tipiracil chloridrate (FTD/ TPI) compared to best supportative care (BSC) and regorafenib for the treatment of polytreated metastatic colorectal carcinoma (mCRC) (3rd line or later lines) in the private payer perspective in Brazil. Methods: A partitioned survival model was developed based on three heath states. Effectiveness was measured in life-years gained and Quality-Adjusted Life Years (QALYs). Costs were obtained from the perspective of the supplementary healthcare system in Brazil considering a time horizon of five years. Univariate and probabilistic sensitivity analyses were performed to evaluate the robustness of the model. Results: The use of FTD/TPI may generate better clinical outcomes versus BSC and resource savings versus regorafenib. FTD/TPI provided more 0,098 years of life per patient and an incremental quality of life of 0,072 compared to BSC. Regarding regorafenib, FTD/ TPI provided a cost reduction of R$ 2.088,49 per patient and similar clinical benefits. Conclusion: FTD/TPI represents a cost-effective treatment option for mCRC compared to regorafenib from the perspective of the supplementary healthcare system in Brazil.